Seres Therapeutics Inc (MCRB)

In September 2025, Canaccord Genuity raised its price target on Seres Therapeutics to $22.00, and the company adopted a co-CEO structure. In October 2025, Seres announced a workforce reduction of approximately 25% and presented new data from its SER-155 Phase 1b trial. In November 2025, Seres reported a net income of $8.2 million for Q3 2025, boosted by the sale of the VOWST business, and received a grant of up to $3.6 million from CARB-X. In January 2026, Seres announced the publication of two studies providing new insights into the VOWST mechanism. As of February 6, 2026, the stock had appreciated by approximately 15.6% since July of the previous year, but concerns about financial constraints and potential dilution risk were noted.

Based on the available information, there is no explicit indication of demand seasonality for Seres Therapeutics' products or services.

Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics that utilize the human microbiome to treat serious diseases. The company's pipeline includes SER-155, an oral live biotherapeutic in Phase 2 development, SER-287 and SER-301 in clinical trials for ulcerative colitis, and SER-401, a preclinical-stage oral microbiome therapy. Seres successfully developed VOWST, the first orally administered microbiome therapeutic for preventing the recurrence of Clostridioides difficile infection (CDI), but sold the VOWST business to Nestlé Health Science in September 2024.

Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States. The company conducts multi-center clinical trials across North America and Europe. Its former commercial product, VOWST, was launched in the U.S. in June 2023.

Seres Therapeutics has a reputation as a pioneering company in microbiome therapeutics, strengthened by the FDA approval of VOWST. The company actively participates in industry conferences and publishes in medical journals, enhancing its scientific reputation. FDA designations for SER-155 further enhance the company's reputation for innovative solutions. A workforce reduction in October 2025 could have affected the company's reputation, but the strategic shift to focus on high-impact clinical programs and the return to profitability demonstrate a proactive approach.

Individual investors hold the largest stake in Seres Therapeutics, possessing 52% of the company's shares. Major institutional owners include Flagship Pioneering Inc., Vanguard Group Inc, Susquehanna International Group, Llp, BlackRock, Inc., Nestlé S.A., and Charles Schwab Investment Management, Inc. In total, 59 institutional owners and shareholders hold 2,186,368 shares.